Stargardt's Syndrome

Overview

Stargardt's disease (also known as fundus flavimaculatus and Stargardt's macular dystrophy) is the most common form of inherited juvenile macular degeneration. Inherited as an autosomal recessive trait, it is a severe form of MD that begins in late childhood, leading to legal blindness. It is symptomatically similar to age-related macular degeneration, and may occur in one of every 20,000 children over the age of 6. It is usually diagnosed before the age of 20, when decreased central vision is first noticed. Boys and girls are equally affected by this condition. Over 25,000 Americans have Stargardt's disease.

Stargardt's disease causes a progressive loss of central vision. In the early stages, patients may have good visual acuity, but they may experience difficulty with reading and seeing in dim lighting.

Treatment

Stargardt's may be treated with microacupuncture and/or microcurrent stimulation (MCS).

Micro Acupuncture™ is a procedure involving 48 newly discovered acupuncture points located only in the hands and feet, and not associated with any other acupuncture system. These points were discovered by Andy Freddy Dahlgren, D.Ss., D. Ac., M.Ac .F., M.D. in Denmark in 1984 and researched by Dr. Dahlgren and Dr. Per G. Otte, D. Sc., D. Ac., M.Ac .F. More than 5,000 people have been treated with this procedure throughout Europe, and over 10,000 people have benefited from Micro Acupuncture treatment in the US. 98% of the patients treated have had a marked improvement in their vision. See Treatment Process Information

MicroCurrent Stimulation (MCS) is an enhanced adaptation of a FDA approved therapy used by anesthesiologists, orthopedic surgeons, plastic surgeons and rehabilitative specialists to promote the healing of wounds and transplanted tissues as well as to treat pain. See Detailed Description

Results